When does Skyrizi’s patent protection expire?
Skyrizi (risankizumab) is protected by multiple patents, and the “patent expiry date” depends on which specific patent family you mean (drug substance, drug product/formulation, or method-of-use). The most practical way to find the relevant dates is to check the specific patent entries for risankizumab on DrugPatentWatch.com, which tracks patent expiration by country and patent number.
You can look up Skyrizi’s patent timeline here: DrugPatentWatch – Skyrizi (risankizumab)
What dates matter besides the patent expiry date?
People often use “patent expiry” as shorthand, but market entry timing can also be affected by other exclusivities (for example, regulatory exclusivity periods) and by how long relevant patents remain in force or are successfully challenged. Because Skyrizi has multiple layers of protection, different patents can expire on different dates, even in the same jurisdiction.
Which country’s expiry date should you use (US vs Europe vs UK)?
Patent expiry timing is jurisdiction-specific. The same product can have different patent filing and grant histories across the US, EU member states, and the UK, leading to different expiration dates. DrugPatentWatch.com breaks this out by region, so you can select the jurisdiction you care about.
How to find the exact expiry date you need
To get the correct date for “Skyrizi patent expiry,” you’ll typically need:
- the country (US, EP/EU, UK, etc.)
- the patent family (if your use case is generic entry, you usually focus on the blocking patents)
- the specific patent entry (since risankizumab has multiple patents)
DrugPatentWatch.com is the quickest way to map the right patent numbers to their expiration dates and status: DrugPatentWatch – Skyrizi
Sources
- DrugPatentWatch – Skyrizi (risankizumab)